Several tyrosine kinase inhibitor (TKI) therapies against EGFR and c-Met are currently administered and are initially effective in NSCLC patients who have certain somatic EGFR-activating mutations such as L858R [3–5]. The gene discussed is MET; the disease is non-small cell lung carcinoma.